- Companies
- Promaxo
Promaxo Funding, Investors & Competitors
Promaxo has raised $129M across 8 funding rounds, most recently a $27M undisclosed-stage round in March 2026.
Last Promaxo funding round
$27M
Undisclosed stage · Mar 2026
Cumulative funding Promaxo raised
$129M
across 8 funding rounds
Key investors in Promaxo
Spark Growth Ventures
MicroPort Scientific
Huami
Almond Tree Capital Fund
Kineticos Disruptor Fund
RocSon Medtech Fund
Zynext Ventures
About Promaxo
Promaxo is a medical technology company developing MRI-compatible robotics and machine learning systems for in-office procedures. Protected by over 55 patents its products include guidance systems disposables and AI-based tissue characterization tools targeting interventional radiology. San Diego-based the firm commercializes customer-centric MRI enhancements for patient care.
Founded
2016
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Promaxo Funding History
Promaxo has raised a total of $129M across 8 funding rounds.
Promaxo's first fundraising round was a $4M Series A in September 2017. The most recent completed round was a $27M undisclosed-stage round in March 2026.
Promaxo funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2026 | Undisclosed stage | - | $27M | - |
| Jun 2024 | Undisclosed stage | Zynext Ventures; Spark Growth Ventures | $42M | Promaxo Inc. is a US-based medical technology company headquartered in Oakland, California, specializing in portable low-field MRI systems and minimally invasive robotics for point-of-care imaging and interventions, particularly targeting prostate biopsy and treatment. The company's compact, open-design MRI system has received FDA 510(k) clearance for prostate applications, enabling use in clinics and operating rooms, and integrates with robotics to enhance precision in guided procedures. Promaxo holds over 200 patents and aims to expand into female pelvic, kidney, breast, and orthopedic areas. On June 18, 2024, Zynext Ventures, the VC arm of Zydus Lifesciences, announced its investment in Promaxo, with Spark Growth Ventures also listed as a participant in related announcements. A funding filing on July 10, 2024, reported Promaxo raising $41.9 million from an offering of $57.3 million, described as Series B3 venture funding led by MicroPort Scientific in some reports. The investment supports acceleration of Promaxo's mission to bring cutting-edge MRI and robotic solutions to market, leveraging partners' healthcare expertise to improve patient outcomes and broaden access. Promaxo has prior traction including an $8 million financing round closed earlier to develop its robotic-guidance system and launch its MRI platform in urology practices. In Q3 2023, the company announced the sale of 20 systems. Affiliates like neuro42 received FDA clearance for a portable brain MRI scanner in February 2024 and a $5 million NIH grant in September 2023 for intraoperative MRI research. The US prostate biopsy and treatment market is approximately $3 billion annually, with 300,000 new cases projected for 2024 and one million biopsies performed. |
| Apr 2024 | Undisclosed stage | Spark Growth Ventures | $32M | Promaxo is a medical technology company developing in-office MRI systems and robotic-guidance technologies for urology practices and enhanced patient care. The company aims to bring MRI and intervention technologies to physicians' offices for improved quality of care. The company has raised a total of $63.1M across multiple rounds, with its latest being a Series C round of $41.94M on April 8, 2024, involving investors including Zynext Ventures. Earlier, Promaxo closed an $8M round from super angels and strategic investors to accelerate clinical launch of its MRI platform and robotic-guidance system. Another reported raise was $41.9M in Series B3 venture funding led by MicroPort Scientific on July 10, 2024. Promaxo's 2023 revenue was $25M. Investors in Promaxo include Zynext Ventures, Fred Moll, Huami, Kineticos Life Sciences, MicroPort, and others, totaling 7 investors. |
| Jan 2021 | Strategic investment | Huami (lead) | $4M | Promaxo is a medical technology company developing AI-powered medical imaging enhancement platforms and compact MRI systems for in-office use, particularly for prostate interventions and guided procedures. The company received U.S. FDA 510(k) clearance in March 2021 for its revolutionary office-based MRI system. In January 2021, Promaxo closed a $4.17 million investment round led by Huami Corporation to accelerate its data strategy and incorporate AI in imaging and interventions. Huami, focused on connecting health with technology, partnered to leverage its miniaturization expertise for Promaxo’s scaling. Promaxo has raised additional funding in later rounds, including an $8 million round from super angels and strategic investors, and a Series C of $41.94 million in 2024, bringing total funding to $63.1 million over multiple rounds. |
| May 2020 | Series B | Kineticos Disruptor Fund (lead) | $11M | Promaxo is an Oakland-based medical technology startup developing a portable single-sided MRI system aimed at making MRIs more versatile and accessible for patients and physicians, particularly in urology. The company focuses on minimally-invasive, patient-centric imaging combined with robotics and AI for point-of-care diagnostic biopsies and cancer treatments, backed by over 90 patents. Funds from the Series B-1 round, announced on May 28, 2020, and led by Kineticos Disruptor Fund with participation from existing investors, support preparation for commercialization in the urology market and continued development of robotic and AI programs. Kineticos Disruptor Fund targets entrepreneur scientists in disruptive platform technologies addressing large unmet medical needs. Promaxo had previously raised equity in earlier rounds, including a Series A in 2018 led by MicroPort Scientific and Series B in 2019. |
| Aug 2019 | Series B | - | $8M | Promaxo is a medical technology company developing in-office MRI systems and robotic-guidance technologies for urology practices and prostate cancer management. The company announced closing an $8M funding round on August 8, 2019, from super angels and strategic investors. Funds were allocated to accelerate the clinical launch of its MRI platform and develop robotic-guidance for live MRI interventions in physicians' offices. Promaxo's MRI technology aims to enhance patient care through office-based high-resolution imaging, supported by over 60 patents. Prior to this round, Promaxo raised $1.4M in seed funding and $3.5M in Series A led by MicroPort Scientific Corporation, which secured exclusive China distribution rights. |
| Apr 2018 | Series A | MicroPort Scientific (lead); Almond Tree Capital Fund; RocSon Medtech Fund | $2M | - |
| Sep 2017 | Series A | MicroPort Scientific (lead) | $4M | Promaxo, Inc. is a medical device company developing office-based, high-resolution MRI technology along with real-time MRI-compatible biopsy and treatment tools, focused on transforming prostate cancer screening, diagnosis, and treatment. The company's MRI platform is protected by 33 issued and pending patents and has received over $9 million in grants from the NIH and NSF. In September 2017, Promaxo closed a $3.5 million Series A funding round led by MicroPort Scientific Corporation, a strategic investor. As part of the investment, MicroPort secured exclusive China distribution and manufacturing rights for Promaxo's MRI technology. Promaxo planned to use the Series A capital, combined with $1.4 million in seed funding raised earlier in 2017, to conduct clinical validation studies and prepare regulatory submissions for its office-based high-resolution MRI system. |
Who has invested in Promaxo?
7 investors have backed Promaxo across its funding rounds, including Spark Growth Ventures, MicroPort Scientific, Huami, Almond Tree Capital Fund, Kineticos Disruptor Fund and RocSon Medtech Fund.
Lead investors include Huami, Kineticos Disruptor Fund and MicroPort Scientific.
Promaxo Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Sep 2017 | ||
| 2 | Participant | Apr 2024 | ||
| 1 | Lead | Jan 2021 | ||
| 1 | Participant | Jun 2024 | ||
| 1 | Lead | May 2020 | ||
This data is available for Pro users. Sign up to see all 7 Promaxo investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialPromaxo Competitors
Promaxo competitors include listed companies like Agilent, GE HealthCare, United Imaging and Siemens, and private ones like Scivita Medical Technology and Carestream.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $6.9B | $1.8B | $44B | 6.2x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Private | - | - | $1.1B | - | ||
| Private | - | - | $800M | - | ||
| Publicly listed | $91B | $15B | $234B | 2.9x |
Promaxo Public Comps
Promaxo is still privately-owned, but its public comps include Samsung, Johnson & Johnson, Roche, Thermo Fisher Scientific, Siemens, Schneider Electric, Abbott, ABB, Hitachi and Danaher.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $243B | $67B | 4.4x | 2.4x | 15.8x | 4.4x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $91B | $15B | 3.0x | 2.9x | 18.1x | 15.7x | |||
| $46B | $9.5B | 4.3x | 3.9x | 21.0x | 18.4x | |||
| $44B | $12B | 4.6x | 4.2x | 17.4x | 15.8x | |||
| $33B | $6.9B | 5.4x | 4.9x | 25.9x | 22.6x | |||
This data is available for Pro users. Sign up to see all Promaxo competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Promaxo
| When was Promaxo founded? | Promaxo was founded in 2016. |
| Where is Promaxo headquartered? | Promaxo is headquartered in San Francisco, CA, United States. |
| Is Promaxo publicly listed? | No, Promaxo is a private, VC-backed company. |
| How much funding has Promaxo raised? | Promaxo has raised $129M across 8 funding rounds. |
| What was Promaxo's last funding round? | Promaxo's last funding round was a $27M undisclosed-stage round in March 2026. |
| Who are Promaxo's investors? | Promaxo's investors include MicroPort Scientific, Spark Growth Ventures, Huami, Zynext Ventures, Kineticos Disruptor Fund, Almond Tree Capital Fund and RocSon Medtech Fund. |
| Which companies are comparable to Promaxo? | Companies comparable to Promaxo include Agilent, GE HealthCare, United Imaging, Scivita Medical Technology, Carestream and Siemens. |
See companies similar to Promaxo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




